CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced that it has signed non-exclusive agreements with New England Biolabs, Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories, Inc. (KPL), whereby the companies have licensed Invitrogen’s patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.
